Comparative Pharmacology
Head-to-head clinical analysis: UNIPEN versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNIPEN versus VERSAPEN.
UNIPEN vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic